Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.

N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of nitrosamines that can potentially be derived from small molecule drugs and their known impurities described in a previous publication, we have now re-analyzed this dataset to apply EMA's Carcinogenic Potency Categorization Approach (CPCA) introduced with the 16th revision of their Q&A document for Marketing Authorization Holders. We find that the majority of potential nitrosamines from secondary amine precursors belongs to potency categories 4 and 5, corresponding to an acceptable daily intake of 1500 ng, whereas nitrosamines from tertiary amine precursors distribute more evenly among all categories, resulting in a substantial number of structures that are assigned the more challenging acceptable intakes of 18 ng/day and 100 ng/day for potency categories 1 and 2, respectively. However, the nitrosative dealkylation pathway for tertiary amine is generally far slower than the direct nitrosation on secondary amines, with a direct nitrosation mechanism suspected only for structures featuring electron-rich (hetero)aromatic substituents. This allows for greater focus towards those structures that require further review, and we demonstrate that their number is not substantial. In addition, we reflect on the nitrosamine risk posed by secondary amine API impurities and demonstrate that based on the ICH Q3A/B identification threshold unknown impurities may exist that could be transformed to relevant amounts of NA. We also demonstrate that the analytical sensitivity required for the quantification of high potency nitrosamines can be problematic especially for high dose APIs. In summary, the regulatory framework rolled out with the latest Q&A document represents a substantial improvement compared with the previous situation, but further refinement through interaction between manufacturers, regulators, not-for-profit and academic institutions will be required to ensure patient access to vital medicines without compromising safety.

A New Paradigm for KIM-PTP Drug Discovery: Identification of Allosteric Sites with Potential for Selective Inhibition Using Virtual Screening and LEI Analysis.

The kinase interaction motif protein tyrosine phosphatases (KIM-PTPs), HePTP, PTPSL and STEP, are involved in the negative regulation of mitogen-activated protein kinase (MAPK) signalling pathways and are important therapeutic targets for a number of diseases. We have used VSpipe, a virtual screening pipeline, to identify a ligand cluster distribution that is unique to this subfamily of PTPs. Several clusters map onto KIM-PTP specific sequence motifs in contrast to the cluster distribution obtained for PTP1B, a classic PTP that mapped to general PTP motifs. Importantly, the ligand clusters coincide with previously reported functional and substrate binding sites in KIM-PTPs. Assessment of the KIM-PTP specific clusters, using ligand efficiency index (LEI) plots generated by the VSpipe, ascertained that the binders in these clusters reside in a more drug-like chemical-biological space than those at the active site. LEI analysis showed differences between clusters across all KIM-PTPs, highlighting a distinct and specific profile for each phosphatase. The most druggable cluster sites are unexplored allosteric functional sites unique to each target. Exploiting these sites may facilitate the delivery of inhibitors with improved drug-like properties, with selectivity amongst the KIM-PTPs and over other classical PTPs.

Targeting Methionine Synthase in a Fungal Pathogen Causes a Metabolic Imbalance That Impacts Cell Energetics, Growth, and Virulence.

There is an urgent need to develop novel antifungals to tackle the threat fungal pathogens pose to human health. Here, we have performed a comprehensive characterization and validation of the promising target methionine synthase (MetH). We show that in Aspergillus fumigatus the absence of this enzymatic activity triggers a metabolic imbalance that causes a reduction in intracellular ATP, which prevents fungal growth even in the presence of methionine. Interestingly, growth can be recovered in the presence of certain metabolites, which shows that metH is a conditionally essential gene and consequently should be targeted in established infections for a more comprehensive validation. Accordingly, we have validated the use of the tetOFF genetic model in fungal research and improved its performance in vivo to achieve initial validation of targets in models of established infection. We show that repression of metH in growing hyphae halts growth in vitro, which translates into a beneficial effect when targeting established infections using this model in vivo Finally, a structure-based virtual screening of methionine synthases reveals key differences between the human and fungal structures and unravels features in the fungal enzyme that can guide the design of novel specific inhibitors. Therefore, methionine synthase is a valuable target for the development of new antifungals.IMPORTANCE Fungal pathogens are responsible for millions of life-threatening infections on an annual basis worldwide. The current repertoire of antifungal drugs is very limited and, worryingly, resistance has emerged and already become a serious threat to our capacity to treat fungal diseases. The first step to develop new drugs is often to identify molecular targets in the pathogen whose inhibition during infection can prevent its growth. However, the current models are not suitable to validate targets in established infections. Here, we have characterized the promising antifungal target methionine synthase in great detail, using the prominent fungal pathogen Aspergillus fumigatus as a model. We have uncovered the underlying reason for its essentiality and confirmed its druggability. Furthermore, we have optimized the use of a genetic system to show a beneficial effect of targeting methionine synthase in established infections. Therefore, we believe that antifungal drugs to target methionine synthase should be pursued and additionally, we provide a model that permits gaining information about the validity of antifungal targets in established infections.

Identification of Functional and Druggable Sites in Aspergillus fumigatus Essential Phosphatases by Virtual Screening.

Fungal diseases are a serious health burden worldwide with drug resistance compromising efficacy of the limited arsenal of antifungals available. New drugs with novel mechanisms of action are desperately needed to overcome current challenges. The screening of the Aspergillus fumigatus genome identified 35 phosphatases, four of which were previously reported as essential for viability. In addition, we validated another three essential phosphatases. Phosphatases control critical events in fungi from cell wall integrity to cell cycle, thus they are attractive targets for drug development. We used VSpipe v1.0, a virtual screening pipeline, to evaluate the druggability of the seven essential phosphatases and identify starting points for drug discovery. Targeted virtual screening and evaluation of the ligand efficiency plots created by VSpipe, enabled us to define the most favourable chemical space for drug development and suggested different modes of inhibition for each phosphatase. Interestingly, the identified ligand binding sites match with functional sites (active site and protein interaction sites) reported for other yeast and human homologues. Thus, the VSpipe virtual screening approach identified both druggable and functional sites in these essential phosphatases for further experimental validation and antifungal drug development.

Proteomic analysis of atrazine exposure in Drosophila melanogaster (Diptera: Drosophilidae).

Atrazine is a widely used herbicide that has been reported to induce the activity of certain detoxification enzymes and to affect insecticide toxicity in organisms experiencing simultaneous exposure to both atrazine and insecticides. In this study, the effects of atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) exposure on protein expression in male and female Drosophila melanogaster adults in both microsomal and cytosolic cell fractions was investigated by 2-dimensional gel electrophoresis. Differentially expressed proteins (vs. controls) were identified using matrix assisted laser desorption-time (MALDI-TOF) of flight mass spectrometry (MS). We identified a total of 28 proteins associated with energy production including glycolysis and mitochondrial respiration as differentially expressed and nine proteins associated with detoxification and response to oxidative stress. Most of these proteins were expressed in one sex or the other but not in both. Surprisingly, the only proteins associated with detoxification were identified as glutathione transferases. No cytochrome P450s were identified which have previously been shown to be responsive to atrazine exposure in D. melanogaster and proposed to be associated with insecticide/atrazine interactions. Results of this investigation support the role of atrazine in affecting mitochondrial electron transport and oxidative stress. However, the role of atrazine in pesticide interactions remains uncertain.

Individual variations in numerically modeled human muscle and temporomandibular joint forces during static biting.

AIMS: To test the effects of occlusal force (OF) angle on the variations in predicted muscle and temporomandibular joint (TMJ) forces during unilateral molar bites. METHODS: The craniomandibular (CM) geometries of 21 individuals were determined from lateral and posteroanterior cephalometric radiographs. These geometries were used in a numerical model based on minimization of muscle effort. This model was previously validated for this subject group through the use of jaw tracking and electromyographic data. The model predicted muscle and TMJ forces associated with static OFs on the right mandibular first molar. OF angle was varied from vertical to 40 degrees in the buccal and lingual directions, in increments of 10 degrees. RESULTS: Intra- and intersubject variations in predicted muscle and TMJ forces for unilateral molar biting were dependent on OF angle and CM geometry. Nonvertical OFs were associated with either large anterior temporalis muscle forces (> 100% of applied OF in 3 subjects) or large inferior lateral pterygoid muscle forces (> 90% of applied OF in 3 subjects). On average, vertically and buccally directed OFs were associated with higher mean contralateral TMJ forces (60% of applied OF, SD 12%). Two subjects had large ipsilateral or contralateral TMJ forces (> 90% of applied OF). CONCLUSION: In a group of healthy subjects, depending on the individual CM geometry, large muscle and/or TMJ forces were predicted to be associated with specific unilateral molar OF angles. Propensities to increased muscle or joint forces may be predisposing factors in the development of myofascial pain or intracapsular disease. The results may explain, in part, the variation in location of symptoms in individuals who first present with temporomandibular disorders.